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Bitter Taste Receptor Agonists 
Mitigate Features of Allergic 
Asthma in Mice
Pawan Sharma1,2, Roslyn Yi1, Ajay P. Nayak1, Nadan Wang1, Francesca Tang2, 
Morgan J. Knight3, Shi Pan1, Brian Oliver2 & Deepak A. Deshpande1
Asthma is characterized by airway inflammation, mucus secretion, remodeling and 
hyperresponsiveness (AHR). Recent research has established the bronchodilatory effect of bitter taste 
receptor (TAS2R) agonists in various models. Comprehensive pre-clinical studies aimed at establishing 
effectiveness of TAS2R agonists in disease models are lacking. Here we aimed to determine the effect of 
TAS2R agonists on features of asthma. Further, we elucidated a mechanism by which TAS2R agonists 
mitigate features of asthma. Asthma was induced in mice using intranasal house dust mite or aerosol 
ova-albumin challenge, and chloroquine or quinine were tested in both prophylactic and treatment 
models. Allergen challenge resulted in airway inflammation as evidenced by increased immune cells 
infiltration and release of cytokines and chemokines in the lungs, which were significantly attenuated 
in TAS2R agonists treated mice. TAS2R agonists attenuated features of airway remodeling including 
smooth muscle mass, extracellular matrix deposition and pro-fibrotic signaling, and also prevented 
mucus accumulation and development of AHR in mice. Mechanistic studies using human neutrophils 
demonstrated that inhibition of immune cell chemotaxis is a key mechanism by which TAS2R agonists 
blocked allergic airway inflammation and exerted anti-asthma effects. Our comprehensive studies 
establish the effectiveness of TAS2R agonists in mitigating multiple features of allergic asthma.
Asthma is a chronic inflammatory disease of the airways affecting over 300 million people worldwide1 and 
characterized by airway inflammation, hyperresponsiveness, mucus hypersecretion and remodeling2–4. The 
chronic and persistent inflammation leads to structural and functional changes in the resident airway cells4–7. G 
protein-coupled receptors (GPCRs) play a vital role in the regulation of airway inflammation, and airway smooth 
muscle (ASM) contraction, relaxation, and proliferation8,9. Therefore, GPCR agonists or antagonists comprise 
mainstay asthma therapies. Identifying a novel class of GPCRs is one of the approaches to developing newer and 
effective anti-asthma drugs.
We recently identified expression of bitter taste receptors (TAS2Rs) on human ASM and demonstrated 
that stimulation with TAS2R agonists results in relaxation of ASM10. Other laboratories confirmed the expres-
sion of TAS2Rs and the bronchodilatory effect of TAS2R agonists in mouse11,12, human13–15 and guinea pig16 
airways. Administration of TAS2R agonists into the mouse lungs results in bronchodilation in both naïve and 
allergen-exposed animals10, and TAS2R expression, signaling, and ASM relaxation and bronchodilatory effects 
are maintained under inflammatory conditions in human asthmatic ASM cells and intact lung slices17. TAS2Rs 
have thus emerged as novel targets in the treatment of obstructive airway diseases such as asthma. Numerous 
other properties of TAS2Rs including the availability of well-established natural and synthetic agonists make 
TAS2Rs an attractive target (reviewed in refs 18 and 19).
Asthma is a complex disease involving multiple pathogenic features including inflammation, mucus secre-
tion, remodeling and bronchoconstriction. We have previously shown that TAS2R agonists are potent broncho-
dilators, yet their effect on key features of asthma remains undetermined. Because beta-agonists exhibit little 
or no anti-inflammatory activity, and no current asthma drugs appear effective in deterring airway remode-
ling, a “multi-tasking” asthma drug capable of inhibiting bronchoconstriction, airway inflammation, and airway 
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remodeling would constitute a novel therapeutic addressing an important, unmet clinical need. Here we used two 
different mouse models of allergic asthma to assess the effect of TAS2R agonists on key features of asthma. Our 
results demonstrate that TAS2R agonists are effective in not only reducing AHR, but also in preventing allergic 
airway inflammation and multiple features of airway remodeling.
Results
Mice were pretreated with TAS2R agonists, chloroquine or quinine by intranasal (HDM model) or aerosol 
(OVA model) route, and challenged with either HDM or OVA as described in Methods and illustrated in Fig. 1. 
Twenty-four hours post-final challenge, lung function, airway inflammation, and features of airway remodeling 
were assessed. Aerosol characterization of chloroquine showed more than 60% of aerosolized drug was contained 
in particles of sufficient size (<3.3 μ m) to reach and deposit in the lower airways (Fig. 1C)20. Aerosolization of 
a 1.5 mg/ml chloroquine solution produced a mean aerosol concentration of 2.6 μ g/L, which corresponds to a 
500 ng dose per 30 minutes treatment.
Effect of TAS2R agonists on allergic airway inflammation. HDM and OVA challenge resulted in a 
robust increase in immune cell infiltration in the airways as demonstrated by a significant increase in cell count 
in the BAL compared to controls. Pretreating mice with TAS2R agonists chloroquine or quinine significantly 
(p < 0.05) reduced infiltration of inflammatory cells (Fig. 2A). This was further confirmed by histological eval-
uation of H&E stained lung sections (Fig. 2B–E). Differential cell count revealed infiltration of eosinophils, 
neutrophils and to a lesser extent accumulation of lymphocytes and macrophages in the BAL. TAS2R agonists 
significantly (p < 0.05) inhibited infiltration of eosinophils, neutrophils and macrophages (Table 1). HDM and 
OVA challenge also caused a significant increase in multiple cytokines and chemokines in the lung, and TAS2R 
agonists inhibited this induction to different degrees (Table 2). HDM exposure in mice specifically led to signif-
icant increases in the levels of pro-eosinophilic-Th2 cytokines (IL-4, IL-5, IL-9 and IL-13), pro-inflammatory 
cytokines eotaxin, KC, TNF-α , IP-10 and RANTES as well as IL-17, a monocyte and neutrophil chemo-attractant 
to the tissue and the anti-inflammatory cytokine IL-10. TAS2R agonists differentially inhibited the induction of 
most cytokines and chemokines, with quinine being more effective than chloroquine in global suppression of 
inflammation.
In OVA-exposed mice there was a significant induction of IL-4, IL-5, IL-13, IL-17, eotaxin, KC, all of which 
were significantly suppressed by TAS2R agonists pretreatment (Table 2). Similarly OVA induced TNF-α , IP-10 
and RANTES, yet TAS2R agonist pretreatment failed to significantly repress the induction of these agents. 
Figure 1. Allergen sensitization and challenge protocols in mice. (A) Male FVB/N mice (8-weeks) were 
injected with 2 mg alum in 0.2 ml PBS or alum with 100 mg ovalbumin (OVA) per mouse on day 1 and day 
14 intraperitoneally. On days 19, 21, 23, 25 and 27 mice were challenged with aerosolized OVA (1%) or saline 
for 30 min. A select set of animals were treated with nebulized chloroquine or quinine (1.5 mg/ml) or vehicle 
for 30 min prior to OVA challenge each day. (B) Female BALB/c mice were challenged with house dust mite 
(HDM, 25 μ g/35 μ l) allergen intranasally as shown in the above schematic: 5 days/week for 3 weeks. 30 min 
prior to HDM challenges, a select set of mice were treated with chloroquine (50 mg/kg) or quinine (10 mg/kg) 
intranasally. 24 h after the last allergen challenge, phenotype was assessed by collecting lung lavage, formalin-
fixed or frozen lung samples, and measuring lung function by flexiVent. Key features of asthma namely airway 
inflammation, remodeling and hyperresponsiveness were assessed respectively. (C) Chloroquine aerosol 
particle size distribution. Aerosolized Chloroquine (1.5 mg/ml) was captured in an Anderson Cascade Impactor 
and quantified by HPLC-MS. Based on the aerosol quantification, each animal received 0.5 μ g per day based on 
30 min of aerosol treatment.
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Collectively, these results indicate that TAS2R agonists demonstrate anti-inflammatory activity in the lung, albeit 
with differential efficacy with respect to specific cytokine suppression and the allergen employed.
Effect of TAS2R agonists on features of airway remodeling. The effect of TAS2R agonists on 
allergen-induced airway remodeling was assessed by determining expression of marker proteins in the BAL or 
lung lysates and by histology. Collagen deposition as assessed by trichrome staining of lung sections was signifi-
cantly lower in lungs of mice treated with TAS2R agonists (Fig. 3A–D). Secreted collagen was significantly higher 
in allergen-challenged animals, and chloroquine or quinine pretreatment significantly (p < 0.05) inhibited this 
response (Fig. 3F). Allergen-induced expression of TGF-β 1 (a marker of pro-fibrotic remodeling) was markedly 
inhibited by chloroquine and quinine (Fig. 3G). TGF-β action on airway cells involves phosphorylation of Smad2, 
and immunoblot analysis of lung lysates revealed inhibition of allergen-induced increase in phospho-Smad2 
by TAS2R agonists (Fig. 3E). Finally, immunoblot analyses of whole lung lysates revealed increased expression 
of fibronectin (Fig. 3H,I) in HDM- or OVA-exposed mice, which was inhibited by pretreatment with TAS2R 
agonists.
Figure 2. TAS2R agonists inhibit allergen-induced airway inflammation. (A) Total BAL cell count was 
performed using a hemocytometer. Histology was performed on formalin-fixed lungs and then stained with 
H&E for assessing tissue inflammation (B,C). Lung inflammation scoring was performed on H&E stained tissue 
slides as described in the methods section using multiple images (3 images/mouse) (D,E). Data shown above 
represent the mean of 8–11 animals in each group; *p < 0.05 (Saline vs HDM or OVA), #p < 0.05 (HDM or OVA 
vs CQ or Q). CQ: chloroquine; Q: quinine.
www.nature.com/scientificreports/
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Immunofluorescence staining of sm-α -actin in lung sections revealed increased smooth muscle around the 
airways in HDM or OVA challenged animals, and TAS2R agonists significantly (p < 0.05) inhibited this induc-
tion (Fig. 4A–D). Moreover, the accompanying allergen-induced increase in smMHC, sm-α -actin, and calponin 
expression in lung lysates was similarly inhibited by chloroquine and quinine pretreatment in HDM (Fig. 4E–H) 
and OVA (Fig. 4I–L) models of allergic asthma.
Increased mucus accumulation is another key feature of asthma. HDM or OVA challenge resulted in exces-
sive accumulation of mucus in the airways (assessed by PAS staining), and pre-treatment with TAS2R agonists 
inhibited this accumulation (Fig. 5A–D). Matrix metalloproteinases (MMPs) have been implicated in asth-
matic airway remodeling. HDM or OVA challenge resulted in robust induction of MMP-8 (neutrophil colla-
genase), pro-MMP-9 (gelatinase) and MMP-12 (macrophage metalloelastase) in BAL fluid, when compared to 
saline-challenged mice (Fig. 5E–J). In the HDM model, TAS2R agonist quinine was more effective than chloro-
quine in blocking induction of MMP-8 and MMP-12 while both TAS2R agonists blocked pro-MMP-9 induction. 
In the OVA model, chloroquine was more effective than quinine in blocking induction of MMP-8 and MMP-12, 
whereas both TAS2R agonists blocked pro-MMP-9 induction. These results suggest that TAS2R agonists differ-
entially regulate MMPs induction in models of allergic asthma.
Effect of TAS2R agonists on airway hyperresponsiveness. Airway responsiveness to MCh challenge 
was determined using anesthetized, intubated and ventilated mice. HDM challenge resulted in an increased 
bronchoconstrictor response to MCh, and pretreatment with TAS2R agonists inhibited development of AHR 
(Fig. 6A). A similar but slightly increased bronchoconstrictor response occurred in OVA-challenged mice, and 
again this was reversed by pretreatment with chloroquine or quinine (Fig. 6B). Furthermore, aerosolized chloro-
quine (250 μ g/ml) and quinine (150 μ g/ml) (administered after the highest concentration of MCh) were able to 
provide effective bronchorelaxation as seen by significant reduction in airway resistance (R) in both HDM- and 
OVA- challenged mice (Fig. 6C,D).
Effect of TAS2R agonists on allergic airway inflammation in treatment model. The ability of 
TAS2R agonists in attenuating various features of allergic airway inflammation was further evaluated in a treat-
ment model. Allergic inflammation was established in mice via intranasal administration of HDM for 3 weeks 
and following this, for next 2 weeks mice were treated with TAS2R agonists, chloroquine or quinine by intranasal 
route, and challenged with HDM (Fig. 7A). Treatment of mice with TAS2R agonists resulted in reduced infil-
tration of the inflammatory cells in the airways and attenuation of histopathological changes in the lung tissue 
(Fig. 7B and C). Significant reductions were observed in accumulation of eosinophils, neutrophils and to lesser 
extent macrophages in the airways following treatment with TAS2R agonists (Table 1). Furthermore, treatment 
with TAS2R agonists resulted in significant reduction in levels of allergen-induced cytokines such as eotaxin, KC, 
IP-10 and RANTES in the airways (Table 3). Repeated instillation of HDM in the airways for 5 weeks resulted is 
extensive collagen deposition around the conducting airways (Fig. 7C), which was attenuated by treatment with 
TAS2R agonists. Furthermore, soluble collagen levels in lung tissue lysates were also significantly lower follow-
ing treatment with TAS2R agonists (Fig. 7D). Pro-fibrotic cytokine TGF-β 1 expression was prominent in mice 
exposed with HDM and its expression was attenuated in mice treated with TAS2R agonists (Table 3). In concert, 
Allergen-
induced asthma 
models
Differential BALF counts (cell numbers ± SEM)
Eosinophils Neutrophils Macrophages Lymphocytes
Prophylactic model 
Allergen – HDM
Saline control 329 ± 170 763 ± 283 60,725 ± 13,721 21,550 ± 4,800
Vehicle + HDM 301,750 ± 22,605* 227,583 ± 16,484* 242,250 ± 20,579* 131,450 ± 20,437*
CQ + HDM 151,909 ± 17,391# 153,655 ± 17,520# 168,227 ± 18,120# 101,936 ± 13,797#
Q + HDM 121,778 ± 6,984# 123,133 ± 12,419# 150,778 ± 17,505# 88,689 ± 15,446#
Allergen - Ovalbumin
Saline control 129 ± 129 2,137 ± 966 164,888 ± 63,857 71,250 ± 25,706
Vehicle + OVA 228,700 ± 40,250* 217,900 ± 17,124* 258,200 ± 34,905 117,590 ± 12,947
CQ + OVA 114,430 ± 6,335# 113,030 ± 6,824# 208,080 ± 37,431 67,120 ± 8,401
Q + OVA 134,900 ± 21,007# 147,330 ± 20,739# 171,660 ± 29,377 98,680 ± 19,500
Treatment model
Allergen - HDM
Saline control 353 ± 234 1079 ± 397 95,911 ± 9,907 39,700 ± 3,994
Vehicle + HDM 222,625 ± 18,383* 274,500 ± 36,029* 302,250 ± 29,842* 149,438 ± 17,656*
CQ + HDM 147,300 ± 10,964# 177,000 ± 14,052# 240,875 ± 20,747 130,750 ± 17,465
Q + HDM 149,000 ± 19,431# 149,375 ± 15,427# 203,750 ± 17,783# 154,683 ± 27,903
Table 1. Differential cell counts (prophylactic model and treatment model). Data shown above represents 
the mean of 8–11 animals in each group; *p < 0.05 (Saline vs HDM or OVA), #p < 0.05 (HDM or OVA vs CQ 
or Q) using 1-way ANOVA. CQ: chloroquine; Q: quinine; OVA: Ovalbumin; HDM: house dust mite; BALF: 
bronchoalveolar lavage fluid; SEM: standard error of means.
www.nature.com/scientificreports/
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we also observed inhibition of HDM-induced accumulation of phospho-Smad2 as well as fibronectin levels by 
treatment with TAS2R agonists (Fig. 7E). Treatment of mice with quinine also resulted in reduced expression of 
sm-α -actin, smMHC and calponin in the lung tissue compared to untreated mice (Fig. 7F and G). Comparable 
effects were observed following treatment with chloroquine, although calponin expression was not affected. 
Treatment with TAS2R agonists also resulted in fewer PAS+ mucus-producing cells in the bronchi and bron-
chioles (Fig. 7H). Finally, treatment with TAS2R agonists resulted inhibition of dose-dependent MCh-induced 
bronchoconstrictor response in HDM-challenged mice (Fig. 7I).
Mechanism of action of TAS2R agonists. As TAS2R receptor agonists exhibited protective effects on 
airway inflammation through attenuated expression of cytokines and chemokines and significant reduction in 
allergen-induced immune cell influx into the mouse lungs, we investigated the potential mechanism for the broad 
anti-inflammatory action of TAS2R agonists. Using peripheral blood neutrophils from healthy human volunteers 
we studied the effect of TAS2R agonists on CXCL8 (IL-8)-mediated chemotaxis of immune cells (neutrophils) 
(Fig. 8). Our results demonstrate dose-dependent reduction in the immune cell recruitment to a chemotactic 
gradient (CXCL8, 100 ng/ml, 90 min) by both TAS2R agonists chloroquine and quinine; the effect being more 
pronounced and significant at 500 μ M and 1 mM respectively.
Our previous study using human ASM cells suggest that TAS2R agonists inhibit mitogen-induced ASM 
growth21. The anti-remodeling effect of TAS2R agonists observed in this study may involve anti-mitogenic effect 
of TAS2R agonists. TAS2R agonists induce efficacious bronchodilation in murine models10–12 and human ASM 
cells/tissues. The bronchodilatory effect may account for an attenuated AHR in animals treated with TAS2R ago-
nists compared to allergen-challenged animals.
Discussion
Recent studies have established the expression of TAS2R on extraoral tissues including ASM. Most importantly, 
stimulation of airways with a variety of TAS2R agonists results in relaxation of airways and bronchodilation. 
Based on this observation TAS2Rs have emerged as novel, promising targets for treating obstructive lung diseases 
such as asthma. To further validate the potential use of TAS2Rs as anti-asthma drug targets, we assessed the 
effectiveness of two different bitter ligands (chloroquine and quinine) delivered by two different routes (intranasal 
and aerosol) in murine models challenged with two different allergens (OVA and HDM). Aerosol quantification 
further confirmed the feasibility of delivering chloroquine to lower airways by aerosol route. Our findings suggest 
that TAS2R agonists mitigate allergen-induced airway inflammation, remodeling, mucus secretion and AHR in 
murine models of asthma.
TAS2Rs are known to be activated by a variety of structurally diverse natural and synthetic compounds. Most 
of the TAS2Rs are broadly tuned in terms of agonist activation. Some of the commonly used bitter tastants include 
chloroquine, quinine, denatonium, aristocholic acid, saccharine, and noscapine. We investigated the effect of two 
TAS2R agonists, chloroquine and quinine on asthma in murine models. The receptor subtype specificity of these 
two bitter tastants has been established using a heterologous expression system22. Chloroquine and quinine bind 
to TAS2R3, 7, 10, and 39, and TAS2R4, 7, 10, 14, 39, 40, 43, 44 and 46, respectively. Although TAS2R expression 
is found on multiple resident airway cells and on immune cells, the subtype of TAS2Rs expressed on different 
types of cells is different. Using broad-tuned ligands allowed us to discern the effect of bitter tastants on multiple 
features of asthma pathogenesis in mice.
TAS2R expression was demonstrated in human leukocytes primarily on lymphocytes (11 different subtypes 
with 3 of them being expressed at significantly high levels in asthmatics) and mast cells (9 different subtypes). 
Stimulation of blood leukocytes with TAS2R agonists resulted in inhibition of LPS-induced release of IL-13, IL-4, 
Cytokines/
Chemokines 
(pg/
ml ± SEM)
Treatment groups
Allergen - HDM Allergen – OVA
Saline control Vehicle + HDM CQ + HDM Q + HDM Saline control Vehicle + HDM CQ + HDM Q + HDM
IL-4 0.16 ± 0.04 14.68 ± 3.70* 7.15 ± 0.90# 6.47 ± 1.27# 0.21 ± 0.06 12.02 ± 1.92* 4.97 ± 0.65# 6.76 ± 1.69#
IL-5 0.47 ± 0.07 34.22 ± 7.06* 15.97 ± 3.92# 18.64 ± 4.61# 0.53 ± 0.09 52.65 ± 6.44* 25.96 ± 6.64# 19.41 ± 5.67#
IL-9 11.64 ± 4.25 37.56 ± 7.53* 30.25 ± 6.48 17.50 ± 6.36# 2.28 ± 0.42 13.08 ± 9.44 10.33 ± 7.80 28.72 ± 11.73
IL-13 0.11 ± 0.06 19.67 ± 3.35* 7.83 ± 2.50# 4.40 ± 1.34# 0.12 ± 0.08 14.32 ± 1.48* 3.25 ± 0.85# 6.12 ± 2.56#
IL-17 0.15 ± 0.05 1.26 ± 0.25* 0.82 ± 0.22 0.84 ± 0.21 0.11 ± 0.05 1.16 ± 0.16* 0.50 ± 0.14# 0.65 ± 0.17#
IL-10 0.48 ± 0.14 66.44 ± 26.52* 21.15 ± 7.81 2.64 ± 0.54# n.d.
Eotaxin 10.54 ± 2.01 98.19 ± 14.78* 62.45 ± 7.89# 39.20 ± 9.41# 13.82 ± 5.31 147.30 ± 43.11* 53.29 ± 11.17# 54.65 ± 10.43#
KC 19.5 ± 1.91 483.80 ± 114.20* 219.90 ± 56.88# 196.70 ± 63.07# 36.77 ± 3.79 766.00 ± 50.93* 480.30 ± 81.20# 501.00 ± 52.83#
TNF-α 1.24 ± 0.43 18.90 ± 3.41* 10.90 ± 2.09# 6.72 ± 1.36# 0.81  ± 0.35 6.61 ± 1.18* 4.14 ± 0.77 4.98 ± 0.67
IP-10 3.48 ± 0.40 26.32 ± 4.80* 18.58 ± 2.42 15.63 ± 2.50# 4.48 ± 1.07 20.02 ± 3.36* 14.44 ± 2.04 14.16 ± 1.61
RANTES 0.14 ± 0.12 8.67 ± 2.30* 3.40 ± 0.80# 2.12 ± 0.42# 0.31 ± 0.20 2.99 ± 0.83* 1.23 ± 0.39 1.86 ± 0.26
Table 2.  BALF Cytokines and chemokines release in prophylactic models. Data shown above represents the 
mean of 8–11 animals in each group; *p< 0.05 (Saline vs HDM or OVA), #p < 0.05 (HDM or OVA vs CQ or Q) 
using 1-way ANOVA. CQ: chloroquine; Q: quinine; OVA: Ovalbumin; HDM: house dust mite extract; SEM: 
standard error of means; KC: keratinocyte chemoattractant; IP-10: interferon-γ -induced protein 10; RANTES: 
regulated on activation, normal T cell expressed and secreted; n.d.: not detected.
www.nature.com/scientificreports/
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IL-5, TNF-α , IL-1β and IFN-γ , all of which are known to play an important role in asthma23. TAS2R agonists 
chloroquine and denatonium inhibited IgE-induced activation of mast cells and degranulation reflected by the 
inhibition of release of PGD2 and histamine24. Mast cell activation is known to contribute to asthma pathogen-
esis and AHR. These two studies demonstrate the potential anti-inflammatory effect mediated via activation 
of TAS2Rs on immune cells. Using two different murine models of allergic asthma, we demonstrate significant 
and clinically relevant inhibition of immune cell infiltration as well cytokines/chemokines release in the lung by 
TAS2R agonists. Our findings also demonstrate a differential regulation of cytokines and chemokines release by 
HDM and OVA in mice. Of note, the anti-inflammatory effects of TAS2R agonists have been demonstrated in the 
upper airways and respiratory epithelium in chronic rhinosinusitis25,26. More importantly our studies using both 
animal models of asthma, and mechanistic studies in humans in vitro clearly demonstrate that TAS2R agonists 
dampen global allergen-induced airway inflammation and have broader application in terms of reducing depend-
ence on inhaled steroids, mainstay maintenance therapy for asthma.
A genomics study recently demonstrated that TAS2R expression is increased in peripheral blood leukocytes, 
and the expression level of TAS2R is correlated with severity of the disease in asthmatics23. Should such an upreg-
ulation of TAS2R with asthma extend to other cells/tissues including ASM, this disease feature would further 
Figure 3. TAS2R agonists mitigate features of fibrotic airway remodeling. Formalin-fixed lungs were stained 
with AFOG (A) or Trichrome (B) for assessing airway fibrosis to HDM and OVA. Airway fibrosis scoring 
was performed as described in the methods for both HDM (C) and OVA (D) models. Immunoblotting was 
performed using the lung lysates to assess pro-fibrotic signaling for p-Smad-2 (E), Fibronectin (H) and β -actin 
was used as a loading control (I). Total soluble collagen (F) was also quantified using a Sircol-collagen assay and 
levels of TGF-β 1 (G) release in the BAL fluid was measured using multiplex array as described in the methods. 
Data shown above represent the mean of 8–11 animals in each group; *p < 0.05 (Saline vs HDM or OVA), 
#p < 0.05 (HDM or OVA vs CQ or Q) using one way ANOVA. HDM: house dust mite; OVA: ovalbumin; CQ: 
chloroquine; Q: quinine, FN: fibronectin.
www.nature.com/scientificreports/
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favor the use of TAS2R agonists as asthma therapeutics given receptor upregulation would help protect against 
receptor desensitization which is believed to limit the therapeutic efficacy of anti-asthma GPCR agonists, includ-
ing the beta-2-adrenoceptor27,28.
Our findings in both the HDM and OVA models suggest a significant inhibition of mucus accumulation in the 
airways when treated with TAS2R agonists. Shah et al.29 demonstrated that TAS2Rs are expressed on ciliary epi-
thelium of airways and stimulation with bitter tastants results in increased ciliary beat frequency and hence might 
hasten mucus clearance. Gene expression data from total RNA isolated from murine lung revealed inhibition of 
allergen-induced upregulation of MUC-5 gene by TAS2R ligands. Therefore, inhibition of mucus synthesis and 
enhancement of clearance represent a means by which bitter tastants mediate the inhibition of mucus accumula-
tion in the lung we observed herein on two different mouse models.
Our results demonstrate that TAS2R agonists inhibit allergen-induced airway remodeling characterized by 
deposition of extracellular matrix proteins such as collagen and fibronectin. Interestingly, ASM mass was also 
decreased in the animals treated with TAS2R agonists. A recent study from our laboratory demonstrated that 
TAS2R agonists chloroquine, quinine and saccharine inhibit mitogen-induced growth of cultured human ASM 
cells in a dose-dependent fashion21. These observations are valuable considering the fact the current anti-asthma 
medications are effective in either inhibiting airway inflammation or reversing bronchoconstriction, but have 
limited or no utility in treating airway remodeling, a important clinical feature in chronic asthmatics5–7,30. ASM 
mass is directly correlated to asthma symptoms in humans31,32.
Figure 4. TAS2R agonists inhibit accumulation of smooth muscle mass upon allergen challenge. Airway 
smooth muscle mass was determined by immunofluorescence method in both HDM (A) and OVA (B) models. 
Stained images were then quantified using Image J analysis software to determine sm-α -actin staining in the 
lungs (C,D). Key smooth muscle marker proteins were assessed by immunoblotting using the lung-lysates in 
the HDM model. Representative western blots (E) and densitometric analyses for smMHC (F), sm-α -actin (G) 
and calponin (H) are shown in the figure. Similarly smooth muscle markers were assessed in the OVA model 
as shown in the representative immunoblots (I) with densitometric analysis for smMHC (J), sm-α -actin (K) 
and calponin (L). β -actin was used as a loading control. Data shown above represent the mean of 8–11 animals 
in each group; *p < 0.05 (Saline vs HDM or OVA), #p < 0.05 (HDM or OVA vs CQ or Q) using 1-way ANOVA. 
HDM: house dust mite; OVA: ovalbumin; CQ: chloroquine; Q: quinine.
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Figure 5. TAS2R agonists inhibit mucus accumulation and MMP release in the airways. Formalin-fixed 
airways were stained with PAS to assess mucus accumulation in the airways in both HDM model (A) and OVA 
model (C). Airway mucus staining was blindly graded using multiple images (3 images/mouse) for both HDM 
(B) and OVA (D). A variety of MMPs were measured in the BAL namely MMP-8 (E,H), proMMP-9 (F,I) and 
MMP-12 (G,J) in HDM and OVA animals respectively. Results are described as pg/ml. Data shown above 
represents the mean of 8–11 animals in each group; *p < 0.05 (Saline vs HDM or OVA), #p < 0.05 (HDM or 
OVA vs CQ or Q) using 1-way ANOVA. CQ: chloroquine; Q: quinine.
www.nature.com/scientificreports/
9Scientific RepoRts | 7:46166 | DOI: 10.1038/srep46166
Beta-agonists, the mainstay rescue medications in asthma, modestly inhibit ASM growth in vitro. Activation 
of PKA is central to ASM relaxation and ASM cell growth inhibition by beta agonists9. TAS2R agonists on the 
other hand do not activate cAMP/PKA pathway, yet induce a robust bronchodilatory and anti-proliferative effect 
on airways21. These studies suggest TAS2R agonists activate novel signal transduction mechanisms in airways 
cells to promote anti-asthma effects. Allergen challenge in murine models resulted in the secretion of TGF-β, 
MMPs and activation of pro-fibrotic signaling (e.g. p-Smad); treating animals with TAS2R agonists inhibited 
all of these features. These findings suggest inhibition of gene expression by TAS2R agonists in airways cells. We 
recently demonstrated that the anti-mitogenic effect of TAS2R agonists on human ASM cells involves inhibition 
of gene expression required for cell cycle progression21.
Lung function measurements in allergen-challenged mice demonstrate the ability of TAS2R agonist pretreat-
ment to inhibit the induction of AHR caused by either HDM or OVA. AHR occurs not only due to calcium sen-
sitization of ASM during inflammation, but is also promoted by structural and functional changes in airway cells 
upon allergen exposure. Herein we demonstrate that not only do TAS2Rs function as effective acute bronchodi-
lators, but can also mitigate features of allergen-induced airway inflammation and remodeling that contribute to 
AHR.
In summary, our studies using two different murine model of asthma demonstrate that TAS2R agonists chlo-
roquine and quinine administered by aerosol or intranasal route inhibit allergen-induced airway inflammation, 
remodeling, mucus production and AHR, four cardinal features of human asthma. TAS2Rs are known to be ubiq-
uitously expressed and regulate a variety of cellular functions. Although several natural and synthetic compounds 
with known pharmacological characteristics are known to activate TAS2Rs, future studies are needed to develop 
TAS2R agonists and antagonists with high affinity and high subtype specificity. Alternately, existing drugs could 
be repurposed for asthma therapy. Advances in medicinal chemistry and computational modeling should catalyze 
the drug discovery process in exploiting TAS2Rs as novel anti-asthma therapeutic target.
Materials and Methods
Chemicals and reagents. Alexa Fluor-conjugated secondary antibodies were obtained from Life 
Technologies (Carlsbad, CA), IRDye-conjugated anti-mouse and anti-rabbit secondary antibodies were obtained 
from LI-COR Biosciences (Lincoln, NE). Mouse anti-smMHC, anti-sm-α -actin, anti-calponin, rabbit anti-fi-
bronectin were obtained from Sigma (St. Louis, MO) and anti-phospho Smad2 and anti-Smad2 antibodies were 
Figure 6. Allergen-induced AHR is diminished upon pre-treatment with TAS2R agonists. Mice were 
subjected to an increased dose of nebulized methacholine (MCh) challenge protocol to assess characteristics of 
respiratory mechanics in HDM (A) and OVA model (B). Animals were treated with aerosolized chloroquine 
or quinine at the end of the highest concentration of MCh and % change in R was computed in HDM (C) or 
OVA (D) group. *P < 0.05, was considered significant for HDM or OVA vs saline and #P < 0.05, was considered 
significant for HDM or OVA vs CQ or Q treated group. Data shown is the mean of 8-11 mice in each group.
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Figure 7. Effect of TAS2R agonists on features of allergic asthma in the treatment model. (A) Female 
BALB/c mice were initially dosed 5 days a week for 3 weeks with 25 μ g of HDM extract. Mice were then treated 
with either chloroquine (CQ, 50 mg/kg) or quinine (Q, 10 mg/kg) or vehicle (1% ethanol) 30 min prior to 
subsequent HDM challenges for additional 2 weeks. (B) Histopathological assessment of tissue inflammation 
was performed on formalin-fixed lung tissue using H&E staining. (C) Formalin-fixed lungs were stained with 
Trichrome for assessing airway fibrosis to HDM. (D) Total soluble collagen in lung tissue was quantified using 
a Sircol-collagen assay. (E) Immunoblotting was performed using the lung lysates to evaluate pro-fibrotic 
signaling for p-Smad-2 and fibronectin (FN). (F) Representative western blots for sm-α -actin, smMHC, and 
calponin are shown. β -actin was used as a loading control. (G) ASM mass was determined by staining formalin-
fixed lung tissue for sm-α -actin using immunofluorescence method. (H) Fixed lungs were stained with PAS to 
assess accumulation of mucus producing cells in the bronchioles. (I) Mice were subjected to an increased dose 
of nebulized methacholine (MCh) challenge protocol to assess features of respiratory mechanics. *P < 0.05, was 
considered significant for HDM or OVA vs saline and #P < 0.05, was considered significant for HDM or OVA vs 
CQ or Q treated group. Data shown is the mean of 8–11 mice in each group.
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purchased from Cell Signaling (Danvers, MA). Sircol collagen assay was obtained from Biocolor Life Sciences, 
UK. Staining kits (PAS, Trichrome), chloroquine, quinine and saccharine were obtained from Sigma. H&E and 
Afog staining kits were obtained from Vector Labs. All other chemicals were of analytical grade.
Human volunteer recruitment. The study was approved by the Human Research Ethics Committee, The 
University of Sydney prior to commencement. All methods were performed in accordance with the relevant 
guidelines and regulations of the institution. Participants were required to be over 18 years of age. Exclusion 
criteria included if they were asthmatic, pregnant, known to faint during venipuncture procedures or had a 
bloodborne infection or condition. All patients provided written informed consent, and basic demographic infor-
mation was collected.
Mouse models of allergic asthma. All animal procedures were approved by the Institutional Animal Care 
Committee of Thomas Jefferson University and University of Maryland, Baltimore. All methods were performed 
in accordance with the relevant guidelines and regulations of the institutions. Animal surgeries were performed 
under tribromoethanol (Avertin, 250 mg/kg) anesthesia.
Prophylactic model. Female BALB/c mice at 8 weeks were intranasally challenged five days a week for three con-
secutive weeks with 25 μ g of house dust mite (HDM) extract (Dermatophagoides pteronyssinus, Greer Labs, USA) 
in 35 μ l saline (Fig. 1A). A select set of mice were administered either chloroquine (50 mg/kg), quinine (10 mg/kg) 
Cytokines/
Chemokines 
(pg/ml ± SEM)
Treatment groups (Allergen – HDM)
Saline control Vehicle + HDM CQ + HDM Q + HDM
Eotaxin 10.39 ± 1.06 66.45 ± 14.91* 37.53 ± 5.71# 25.73 ± 5.23#
KC 32.58 ± 3.43 183.20 ± 33.34* 105.10 ± 19.25# 111.30 ± 14.34#
IP-10 4.32 ± 0.33 16.49 ± 3.26* 8.80 ± 1.59# 8.36 ± 1.33#
RANTES 4.98 ± 0.50 11.93 ± 2.24* 5.70 ± 0.74# 5.10 ± 0.68#
TGF-β 1 47.48 ± 6.21 2518.00 ± 279.50* 1681.00 ± 220.50# 1552.00 ± 165.50#
Table 3.  Treatment model for HDM-induced allergic airway disease. Data shown above represents the mean 
of 8–11 animals in each group; *p< 0.05 (Saline vs HDM), #p< 0.05 (HDM vs CQ or Q) using 1-way ANOVA. 
CQ: chloroquine; Q: quinine; HDM: house dust mite extract; SEM: standard error of means; KC: keratinocyte 
chemoattractant; IP-10: interferon-γ -induced protein 10; RANTES: regulated on activation, normal T cell 
expressed and secreted; TGF-β 1: transforming growth factor beta 1.
Figure 8. Effect of TAS2R agonists on neutrophil chemotaxis. The neutrophil chemotaxis or migration to 
CXCL8 was measured using Transwell inserts. Isolated and purified peripheral human blood neutrophils were 
plated at desired density in the upper chamber of the Transwell with or without TAS2R agonists (CQ and Q) 
at increasing concentrations (100 μ M, 500 μ M and 1 mM) for 90 minutes at 37 °C while a chemotactic gradient 
was created using IL-8 (100 ng/ml) in the lower chamber of the Transwell plate. The results are expressed as fold 
change in cell migration from upper well to lower well and expressed as neutrophil migration index relative to 
control, which is kept as 1. Data shown above represent the mean of 5-human donors in each group; *p < 0.05 
(Control vs IL-8), #p < 0.05 (IL-8 vs CQ or Q) using 1-way ANOVA. CQ: chloroquine; Q:quinine.
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or vehicle (1% ethanol) in 25 μ l volume by intranasal route 30 min prior to the HDM challenges. Similarly, mice 
were sensitized by injecting 2 mg alum in 0.2 ml PBS or alum with 100 μ g ovalbumin (OVA) per mouse on day 1 
and day 14 intraperitoneally (Fig. 1B). Mice were then challenged with aerosolized sterile PBS with or without 1% 
OVA on days 19, 21, 23, 25 and 27 for 30 min. Select sets of animals were treated with 1.5 mg/ml chloroquine or 
quinine for 30 min by aerosol prior to OVA challenge. Twenty-four hours after the last challenge, lung function 
measurements were performed, bronchoalveolar lavage (BAL) fluid was collected, fresh or formalin-fixed lungs 
were harvested.
Treatment model. Female BALB/c mice (8 weeks old) were initially challenged 5 days a week for 3 weeks via 
intranasal administration of 25 μ g of HDM extract in 35 μ l saline. Following this, mice were treated with chloro-
quine (50 mg/kg), quinine (10 mg/kg) or vehicle (1% ethanol) in 25 μ l volume by intranasal route 30 min prior to 
subsequent HDM challenges for additional 2 weeks. Twenty-four hours following the last challenge, lung function 
measurements were performed, bronchoalveolar lavage (BAL) fluid was collected and fresh or formalin-fixed 
lungs were harvested for downstream analyses.
Aerosol characterization and quantification. Chloroquine was dissolved in water to a concentration of 
1.5 mg/ml. Drug was nebulized by an AirLife Misty Max 10 nebulizer with 10 liter/min of air and captured by an 
Anderson Cascade Impactor (3 M) or glass impinger (Ace) according to standard practice. Collected samples and 
standards were then separated on a Luna 3 u Phenyl-Hexyl column (Phenomenex), peaks were ionized (Acquity 
TQD) and analyzed using Mass Lynx (v4.1).
Assessment of BAL cellularity. BAL samples were subjected to centrifugation and cell pellet resuspended 
in 1 ml PBS. Total cell count in BAL samples was determined by hemocytometer and data expressed as cells/ml. 
The BAL cells after centrifugation were stained with Hema-3 staining kit (Fisher Scientific) and differential cell 
count was determined by brightfield microscope.
Measurement of BAL cytokines and chemokines. The content of cytokines and chemokines in BAL 
fluids were measured by Multiplexing LASER Bead Technology (Eve Technologies, Calgary, Canada) using a 
31-Plex-mouse cytokine/chemokine array (Cat #: MD31) and expressed as pg/ml.
Preparation of Lung Lysates. Mouse lungs were cut into small pieces in 250 μ l of lysis buffer (40 mM Tris, 
150 mM NaCl, 1% IgepalCA-630, 1% deoxycholic acid, 1 mM NaF, 5 mM β -glycerophosphate, 1 mM Na3VO4, 10 μ g/ml 
aprotinin, 10 μ g/ml leupeptin, 7 μ g/ml pepstatin A, 1 mM PMSF, pH 8.0). Lung tissues were homogenized using 
a polytron. The lysate was centrifuged (760 × g, 5 min) and the supernatant stored at − 80 °C for subsequent 
analyses.
Immunoblotting. Protein concentration was determined by Pierce BCA assay kit (Thermo Scientific, 
Rockford, IL) and subjected to immunoblot analysis using protocols described previously10,33 with primary anti-
bodies noted above (1:1000), followed by incubation with respective secondary antibodies (LI-COR Biosciences) 
(1:5000). Immunoblots were visualized and bands quantified using the Odyssey infrared imaging system 
(LI-COR Biosciences).
Soluble Collagen Assay. Total soluble collagen content in the lung lysates was assessed using Sircol collagen 
assay (Biocolor, UK) according to the manufacturer’s protocol as per34. Collagen assay was performed by mixing 
lung homogenates with Sircol Dye reagent and measuring absorbance using a plate reader. Collagen content was 
quantified using a standard curve generated by reference standards and was normalized to the total lung protein 
content in each sample.
Histopathological analysis. Paraffin embedded tissues were used for histological evaluation as described 
previously33,35–37, using 5 μ m sections mounted on Superfrost Plus slides. Slides were deparaffinized, rehydrated 
and subjected to heat-induced epitope retrieval. The sections after blocking were stained with the primary anti-
body (1:100 anti-sm-α -actin) at 4 °C overnight followed by staining with 1:250 goat anti-mouse Alexa Fluor 
conjugated secondary antibody at room temperature for 1 hour. The sections were washed in PBS and stained 
with Draq5 for 15 minutes. Finally, the sections were washed, mounted with Prolong Antifade (Molecular Probes, 
USA), and fluorescent imaging performed using an Olympus BX-51 fluorescent microscope. The lung tissues 
fixed in 10% formalin, embedded in paraffin were cut and stained with H&E, trichrome blue, AFOG and PAS 
staining using a standard histological protocol36. Image acquisition and analysis was performed using a brightfield 
microscope.
Lung inflammatory changes were graded using a semi-quantitative scoring system based on the following 
parameters: peribronchial inflammation and degree of total cell infiltration. Peribronchial inflammation was 
graded on a scale of 0–4 with 0, absent; 1, slight; 2, mild; 3, moderate; and 4, severe. The degree of cell infiltration 
was scored of 0–3 with 0, no cells; 1, few cells; 2, moderate influx of cells; and 3, extensive influx of cells. The total 
lung inflammation score was expressed as the sum of the scores for each parameter.
Similarly, airway fibrosis in the formalin-fixed lung tissue was analyzed using AFOG or Trichrome stain and 
scored by using a scoring system for measuring subepithelial fibrosis (increased content of ECM protein such as 
collagen, stains blue with AFOG and Trichrome). A scoring range of 0–3 was used with 0, none; 1, infrequent; 2, 
common; and 3, widespread; blue staining in the airway wall.
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Peripheral blood neutrophil isolation and migration assay. Neutrophils were isolated from periph-
eral blood collected from volunteers as previously described38–40. Briefly, 40 ml of blood was mixed with 10 ml 
acid citrate dextrose (ACD), 10 ml of phosphate buffered saline (PBS) (Gibco, Carlsbad, CA, USA), and 6 ml 
of 10% dextran (MP Biomedicals, Santa Ana, USA) and left for 20 minutes for sedimentation to occur at room 
temperature. The top layer was removed, overlaid on Ficoll Paque-PLUS (GE Healthcare, Little Chalfont, UK), 
and centrifuged at 490 g for 10 minutes. The supernatant was discarded and the cell pellet of granulocytes was 
resuspended in sterile water for 30 seconds to lyse remaining red blood cells before osmolarity was reestablished 
with equal parts of 2x PBS. Cells were then incubated for 30 minutes at 4 °C with CD16 magnetic beads (Miltenyi 
Biotec, Bergisch, Germany) before running through a magnetic column as per the manufacturer’s instructions. 
Previous optimization of the protocol showed typical purity was 99% or greater by a haematoxylin and eosin 
stain. Neutrophils were resuspended in 1% FBS, 1% 1 M HEPES, and 1% penicillin/streptomycin RPMI 1640 
at 5 × 106 cells/ml and were co-incubated (250,000 cells/well) with TAS2R agonists (chloroquine and quinine; 
100 μ M, 500 μ M and 1 mM) in the upper well of the Transwell inserts (Corning, Corning, New York, USA) while 
CXCL8 (100 ng/ml, R&D Biosciences, USA) was added to stimulate cell chemotaxis in the lower well. Following 
an incubation period (90 min at 37 °C, 5% CO2), the cells that have migrated through the membrane were stained 
with trypan blue and manually counted.
Measurement of Lung Mechanics. Lung mechanics was measured using a flexiVent system (Scireq, 
Canada) as described previously10,35,36,41. Anesthetized and intubated mouse was ventilated with a tidal volume of 
250 μ l at 150 breaths/minute. A PEEP of 3 cm H2O was used for all studies. Mice were subjected to an increased 
dose of nebulized methacholine (MCh) challenge protocol using an in-line ultrasonic nebulizer. Using low fre-
quency forced oscillation technique, respiratory mechanical input impedance (Zrs) was derived from the dis-
placement of the ventilator’s piston and the pressure in its cylinder. By fitting Zrs to the constant phase model, 
flexiVent software calculated airway resistance (R), which was normalized to body weight. Change in lung resist-
ance (R) was recorded for each dose of MCh. Animals were treated with aerosolized chloroquine (250 μ g/ml) or 
quinine (150 μ g/ml) at the end of MCh challenge and change in lung resistance recorded.
Data analyses. Values reported for all data represent means ± standard error of means (SEM). For all stud-
ies, replicate data from at least 8–11 mice were obtained. The statistical significance of differences between two 
means was determined by one-way or two-way ANOVA with Bonferroni’s multiple comparison test for com-
parison between treatments or Tukey’s multiple comparison test. Differences were considered to be statistically 
significant when p < 0.05.
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